Torsten Dreier

Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody

Torsten Dreier, Grit Lorenczewski, Christian Brandl et al. · International Journal of Cancer · 2002 · 349 citations · Full text

Immunology, Immunologic Mechanism, Cd4 T Cell Responses +19

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans

Peter Ulrichts, Antonio Guglietta, Torsten Dreier et al. · Journal of Clinical Investigation · 2018 · 334 citations · Full text

Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen‐induced arthritis

Ken Coppieters, Torsten Dreier, Karen Silence et al. · Arthritis & Rheumatism · 2006 · 296 citations

Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

Bernard M. Tijink, Toon Laeremans, Marianne Budde et al. · Molecular Cancer Therapeutics · 2008 · 289 citations

Nanoparticles, Nanotherapeutics, Engineering +21

Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis

Klaas Vandenbroucke, Hans de Haard, Els Beirnaert et al. · Mucosal Immunology · 2009 · 279 citations

Inflammation, Nanomedicine, Anti-inflammatory +10